Background Variation in cancer survival persists between comparable nations and appears to be due, in part, to primary care practitioners (PCPs) having different thresholds for acting definitively in response to cancer-related symptoms. Aim To explore whether cancer guidelines, and adherence to them, differ between jurisdictions and impacts on PCPs' propensity to take definitive action on cancer-related symptoms. Design and setting A secondary analysis of survey data from six countries (10 jurisdictions) participating in the International Cancer Benchmarking Partnership. Method PCPs' responses to five clinical vignettes presenting symptoms and signs of lung (n = 2), colorectal (n = 2), and ovarian cancer (n = 1) were compared with investiga...
bjectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 coun...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Abstract Background Survival rates following a diagno...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
This is the final version of the article. Available from Royal College of General Practitioners via ...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
OBJECTIVES: The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 co...
Objectives: Cancer survival rates vary widely between European countries, with differences in timeli...
Background: Guideline adherence remains a challenge in clinical practice, despite guidelines’ ascrib...
Background: Guideline adherence remains a challenge in clinical practice, despite guidelines' ascrib...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Background The International Cancer Benchmarking Partnership (ICBP), is a collaboration between six...
bjectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 coun...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Abstract Background Survival rates following a diagno...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
This is the final version of the article. Available from Royal College of General Practitioners via ...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
OBJECTIVES: The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 co...
Objectives: Cancer survival rates vary widely between European countries, with differences in timeli...
Background: Guideline adherence remains a challenge in clinical practice, despite guidelines’ ascrib...
Background: Guideline adherence remains a challenge in clinical practice, despite guidelines' ascrib...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Background The International Cancer Benchmarking Partnership (ICBP), is a collaboration between six...
bjectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 coun...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Abstract Background Survival rates following a diagno...